Dik Heg
Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.
Greutmann M, Tobler D, Engel R, Heg D, Mueller A, Frenk A, Gabriel H, Rutz T, Buechel R, Willhelm M, Trachsel L, Freese M, Ruperti-Repilado F, Valsangiacomo Buechel E, Beitzke D, Haaf P, Wustmann K, Schwitz F, Possner M, Schwitter J, Bouchardy J, Schwerzmann M, SERVE Investigators. Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE. Eur J Heart Fail 2023; 25:1105-1114.
Jun 13, 2023Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.
Jun 13, 2023Eur J Heart Fail 2023; 25:1105-1114
Greutmann Matthias, Tobler Daniel, Engel Reto, Heg Dik, Mueller Arndt-Christian, Frenk André, Gabriel Harald, Rutz Tobias, Buechel Ronny Ralf, Willhelm Matthias, Trachsel Lukas, Freese Michael, Ruperti-Repilado Francisco Javier, Valsangiacomo Buechel Emanuela, Beitzke Dietrich, Haaf Philip, Wustmann Kerstin, Schwitz Fabienne, Possner Mathias, Schwitter Juerg, Bouchardy Judith, Schwerzmann Markus, SERVE Investigators
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.
Lenoir A, Christe A, Ebner L, Beigelman-Aubry C, Bridevaux P, Brutsche M, Clarenbach C, Erkosar B, Garzoni C, Geiser T, Guler S, Heg D, Lador F, Mancinetti M, Ott S, Piquilloud L, Prella M, Que Y, von Garnier C, Funke-Chambour M. Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study. Respiration 2022:1-14.
Dec 23, 2022Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung Study.
Dec 23, 2022Respiration 2022:1-14
Lenoir Alexandra, Christe Andreas, Ebner Lukas, Beigelman-Aubry Catherine, Bridevaux Pierre-Olivier, Brutsche Martin, Clarenbach Christian, Erkosar Berra, Garzoni Christian, Geiser Thomas, Guler Sabina A, Heg Dik, Lador Frederic, Mancinetti Marco, Ott Sebastian R, Piquilloud Lise, Prella Maura, Que Yok-Ai, von Garnier Christophe, Funke-Chambour Manuela
Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial
Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. Int J Cardiol 2021; 334:37-41.
Apr 20, 2021Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial
Apr 20, 2021Int J Cardiol 2021; 334:37-41
Iglesias Juan F, Windecker Stephan, Valgimigli Marco, Heg Dik, Kaiser Christoph, Weilenmann Daniel, Kurz David J, Roffi Marco, Losdat Sylvain, Muller Olivier, Pilgrim Thomas
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial
Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. Cardiovasc Revasc Med 2021; 34:3-10.
Feb 25, 2021Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial
Feb 25, 2021Cardiovasc Revasc Med 2021; 34:3-10
Iglesias Juan F, Windecker Stephan, Jüni Peter, Valgimigli Marco, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Brinkert Miriam, Muller Olivier, Tüller David, Degrauwe Sophie, Roffi Marco, Heg Dik, Pilgrim Thomas
Effect of acute myocardial ischemia on inferolateral early repolarization
Stoller M, Böhler A, Bloch N, Seiler C, Heg D, Branca M, Roten L. Effect of acute myocardial ischemia on inferolateral early repolarization. Heart Rhythm 2020; 17:922-930.
Jan 23, 2020Effect of acute myocardial ischemia on inferolateral early repolarization
Jan 23, 2020Heart Rhythm 2020; 17:922-930
Stoller Michael, Böhler Alexander, Bloch Nando, Seiler Christian, Heg Dik, Branca Mattia, Roten Laurent
Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. J Am Heart Assoc 2019; 8:e013607.
Nov 7, 2019Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
Nov 7, 2019J Am Heart Assoc 2019; 8:e013607
Iglesias Juan F, Windecker Stephan, Jüni Peter, Valgimigli Marco, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Moarof Igal, Muller Olivier, Rigamonti Fabio, Lanz Jonas, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet 2019; 394:1243-1253.
Sep 2, 2019Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial
Sep 2, 2019Lancet 2019; 394:1243-1253
Iglesias Juan F, Windecker Stephan, Jüni Peter, Zwahlen Marcel, Odutayo Ayodele, Valgimigli Marco, Eeckhout Eric, Losdat Sylvain, Stortecky Stefan, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Moarof Igal, Kurz David J, Roffi Marco, Heg Dik, Muller Olivier, Pilgrim Thomas
Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. Circ Cardiovasc Interv 2019; 12:e008024.
Aug 6, 2019Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial
Aug 6, 2019Circ Cardiovasc Interv 2019; 12:e008024
Iglesias Juan F, Windecker Stephan, Jüni Peter, Häner Jonas, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Moarof Igal, Muller Olivier, Noble Stéphane, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas
Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial
Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet 2018; 392:737-746.
Aug 28, 2018Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial
Aug 28, 2018Lancet 2018; 392:737-746
Pilgrim Thomas, Jüni Peter, Eberli Franz R, Hunziker Lukas, Cuculi Florim, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Siontis George C M, Moarof Igal, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Piccolo Raffaele, Windecker Stephan
A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention 2018; 14:692-699.
Aug 20, 2018A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial
Aug 20, 2018EuroIntervention 2018; 14:692-699
Iglesias Juan F, Windecker Stephan, Jüni Peter, Eeckhout Eric, Valgimigli Marco, Heg Dik, Tapponnier Maxime, Kaiser Christoph, Weilenmann Daniel, Vuilliomenet André, Kurz David J, Roffi Marco, Zaugg Serge, Muller Olivier, Pilgrim Thomas
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
Pilgrim T, Jüni P, Wenaweser P, Blöchlinger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. EuroIntervention 2015; 11
Dec 23, 2015Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction
Dec 23, 2015EuroIntervention 2015; 11
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Blöchlinger Stefan, Nietlispach Fabian, Rigamonti Fabio, Taniwaki Masanori, Khattab Ahmed A, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Piccolo Raffaele, Windecker Stephan
Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv 2015; 8
Jun 1, 2015Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial
Jun 1, 2015Circ Cardiovasc Interv 2015; 8
Franzone Anna, Jüni Peter, Wenaweser Peter, Stortecky Stefan, Räber Lorenz, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Muller Olivier, Vuilliomenet André, Tüller David, Roffi Marco, Heg Dik, Pilgrim Thomas, Windecker Stephan
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet 2014; 384:2111-22.
Sep 1, 2014Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Sep 1, 2014Lancet 2014; 384:2111-22
Pilgrim Thomas, Jüni Peter, Wenaweser Peter, Eberli Franz R, Noble Stéphane, Moschovitis Aris, Fahrni Therese, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Heg Dik, Windecker Stephan
Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. Am Heart J 2014; 168:256-61.
Jun 6, 2014Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial
Jun 6, 2014Am Heart J 2014; 168:256-61
Pilgrim Thomas, Jüni Peter, Heg Dik, Jamshidi Peiman, Kaiser Christoph, Weilenmann Daniel, Cook Stéphane, Vuilliomenet André, Muller Olivier, Tüller David, Roffi Marco, Windecker Stephan